Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.92 |
| ▸ | EGFR | P00533 | 3/20 | 0.68 |
| ▸ | PLK1 | P53350 | 3/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | INSR | P06213 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.64 |
| ▸ | ROS1 | P08922 | 1/20 | 0.64 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.64 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18843604 | 0.96 | ALK (1.00) | ALKEGFRPLK1AURKAINSR | |
| SCHEMBL18843603 | 0.95 | ALK (0.83) | ALKEGFRPLK1AURKAINSR | |
| SCHEMBL18843602 | 0.91 | ALK (0.81) | ALKEGFRPLK1AURKAINSR | |
| SCHEMBL18843491 | 0.90 | ALK (0.87) | ALKEGFRPLK1AURKAINSR | |
| SCHEMBL18843514 | 0.89 | ALK (0.78) | ALKEGFRPLK1AURKAINSR | |
| SCHEMBL18843550 | 0.89 | ALK (0.78) | ALKEGFRPLK1AURKAINSR | |
| SCHEMBL18843518 | 0.88 | ALK (1.00) | ALKEGFRPLK1AURKAINSR | |
| SCHEMBL18843512 | 0.87 | ALK (0.87) | ALKEGFRPLK1AURKAINSR | |
| SCHEMBL18843489 | 0.87 | ZAP70 (0.82) | ALKEGFRPLK1AURKAINSR | |
| SCHEMBL18843517 | 0.85 | ALK (1.00) | ALKEGFRAURKAINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372594-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | HUMANWELL HEALTHCARE GROUP CO LTD (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-10695347-B2 | Pyrimidine derivative and use thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-06-30 | — | — | US | disclosed |
| WO-2017076355-A1 | PYRIMIDINE DERIVATIVE AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695347-B2 | Pyrimidine derivative and use thereof | ALK, DPYD, TYMP | ALK 1/4885EGFR 1111/4885PLK1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.